A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

A Long-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder

The objective of this study is to investigate the safety and efficacy of aripiprazole orally administered over long term in subjects who complete a short-term treatment study of pediatric Autistic Disorder (031-11-002 study).

Inclusion Criteria:

• The patient meets Autistic disorder diagnostic criteria defined in DSM-IV-TR.
• The patient has completed the 031-11-002 study (the patient has visited the hospital during week8)
• Inpatient or outpatient status

Exclusion Criteria:

• The patient is currently diagnosed with another disorder on the autism spectrum in DSM-IV-TR, including Asperger's, Rett's Disorder, PDD-NOS, Childhood Disintegrative Disorder, or Fragile-X Syndrome.
• Patients who fall under a contraindication listed in the ABILIFY package insert
• Others